drugset
drugset / Trial / NCT04488900

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

NCT04488900 ↗

Phase 1 Completed 88 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a first-in-human, randomized, placebo-controlled, 4-part, single ascending dose and multiple ascending dose study. The study is designed to assess the safety, tolerability, PK, and PD and food effect of orally administered CKD-508 capsules and tablets in healthy subjects.

Timeline

Start
2020-07-06
Primary completion
2023-07-02
Completion
2023-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-508 Unknown — Oral

Indications

No indication recorded.